| Schedule of computation of basic and diluted (losses)/net earnings per common share |
| | | | | | | | | | | | | | | Three months ended | | Six months ended | | | June 30, | | June 30, | | | 2025 | | 2024 | | 2025 | | 2024 | Basic numerator: | | | | | | | | | | | | | Net loss attributable to XWELL, Inc. | | $ | (2,269) | | $ | (1,996) | | $ | (6,988) | | $ | (4,508) | Less: preferred stock dividends | | | (189) | | | — | | | (257) | | | — | Less: preferred stock accretion | | | (583) | | | — | | | (1,082) | | | — | Net loss attributable to common shareholders | | $ | (3,041) | | $ | (1,996) | | $ | (8,327) | | $ | (4,508) | Basic denominator: | | | | | | | | | | | | | Basic weighted average shares outstanding | | | 5,417,271 | | | 4,182,617 | | | 5,340,442 | | | 4,182,959 | Basic loss per share | | $ | (0.56) | | $ | (0.48) | | $ | (1.56) | | $ | (1.08) | | | | | | | | | | | | | | Net loss per share data presented above excludes from the calculation of diluted net loss, the following potentially dilutive securities, having an anti-dilutive impact, in case of net loss | | | | | | | | | | | | | Both vested and unvested options to purchase an equal number of shares of Common Stock | | | 944,554 | | | 415,388 | | | 944,554 | | | 415,388 | Unvested RSUs to issue an equal number of shares of Common Stock | | | 30,000 | | | 5,208 | | | 30,000 | | | 5,208 | Series A and Series B warrants to purchase shares of Common Stock | | | 5,347,594 | | | — | | | 5,347,594 | | | — | Series G Convertible Preferred Stock on an as converted basis | | | 2,406,417 | | | — | | | 2,406,417 | | | — | Total number of potentially dilutive securities excluded from the calculation of loss per share attributable to common shareholders | | | 8,728,565 | | | 420,596 | | | 8,728,565 | | | 420,596 |
|